Table I.
Baseline patients' features
| Demographic characteristics | |
|---|---|
| Median age (y) (IQR) | 56 (42-68) |
| Sex: M/F | 63/24 (72%/28%) |
| Allergy characteristics | Concomitant conditions | ||
|---|---|---|---|
| Pre-VIT reaction, n (%) | Comorbidities, n (%) | 45 (52) | |
| Mueller 1 | 4 (5) | Cardiovascular | 38 (43) |
| Mueller 2 | 10 (11) | Respiratory | 7 (8) |
| Mueller 3 | 24 (28) | Mast cell disease | 4 (5) |
| Mueller 4 | 49 (56) | Diabetes mellitus | 4 (5) |
| Other | 3 (3) | ||
| Prepandemic skin reactivity (μg/mL), n (%)∗ | |||
| 1 | 29 (33) | Potential mast cell disorder (ie, REMA score ≥2), n (%) | 25 (29) |
| 0.1 | 30 (34) | ||
| 0.01 | 12 (14) | STL ≥11.5 (median, 5.4 μg/L), n (%) | 9 (10) |
| 0.001 | 10 (11) | ||
| 0.0001 | 3 (3) | Treatments, n (%) | 41 (47) |
| ACE inhibitors | 10 (11) | ||
| Venom | Sartanics | 19 (22) | |
| A | 22 (25) | Beta-blockers | 8 (9) |
| VC | 5 (6) | Calcium-channel blockers | 10 (11) |
| P | 15 (17) | Other antihypertensives | 13 (15) |
| V | 36 (41) | Cardiac (anticoagulants, antiarrhytmics) | 11 (13) |
| P + V | 9 (10) | Statins | 9 (10) |
| Asthma inhalers | 2 (2) | ||
| VIT characteristics | |
|---|---|
| VIT duration, n (%) | |
| y ≤ 1† | 13 (15) |
| 1< y ≤2 | 11 (13) |
| 2< y ≤5 | 24 (28) |
| 5< y ≤10 | 25 (29) |
| y >10 | 14 (16) |
| Overall mean VIT duration (min-max) | 6.1 ± 5.5 y (0-30) |
| Mean prepandemic VIT interval (min-max) | 7.0 ± 2.3 wk (2-12) |
| Type of extract, n (%) | |
| Aqueous | 4 (5) |
| Depot | 83 (95) |
| Restung patients, n (%)‡ | 41 (47) |
| Systemic SEs to VIT, n (%) | 1 (1) |
A, Apis mellifera; ACE, angiotensin-converting enzyme; F, female; IQR, interquartile range; M, male; P, Polistes dominula; V, Vespula germanica; VC, Vespa crabro.
∗
Skin test not performed in 3 children because of serological diagnosis. Mean time interval between the first postpandemic visit and the last skin test: 28.8 mo (min-max, 1 mo-5 y).
†
Mean VIT duration: 9 mo (min-max, 1-18 mo).
‡
Reaction in 2 patients.